Fosamax vs Evenity (Romosozumab): Titration Speed, Tolerability, and How to Choose

What Is the Core Difference Between Fosamax and Evenity?

Alendronate (Fosamax) works by one mechanism only: it slows the osteoclasts that resorb bone, preserving what you already have. Romosozumab (Evenity) does something more unusual. It inhibits sclerostin, a protein that normally puts the brakes on bone formation, so it simultaneously accelerates new bone building and slows breakdown. That dual action is why bone mineral density (BMD) gains at the lumbar spine can reach 13% after 12 months on romosozumab versus roughly 4-5% with alendronate alone.

The tradeoff is real. Alendronate has 30 years of safety data in women. Romosozumab has been available since 2019, carries a boxed cardiovascular warning, and is capped at 12 doses total. These are not interchangeable drugs. They occupy different positions in your treatment sequence.

How Each Drug Fits Into the Bone-Remodeling Cycle

Your skeleton constantly tears down old bone (resorption) and deposits new bone (formation). After menopause, falling estrogen tips this balance sharply toward resorption. Alendronate blocks the resorption side but does not meaningfully stimulate the formation side.

Romosozumab acts earlier in the signaling chain. By blocking sclerostin, it releases the inhibition on osteoblasts (your bone-building cells) while also reducing osteoclast activity. The net result is a short but powerful anabolic window, which is why the drug is approved for only 12 months.

Titration Speed: Which Drug Builds Bone Faster?

Romosozumab wins on speed, and it is not close.

Alendronate: Gradual, Steady Gains

Alendronate begins suppressing bone turnover markers within weeks, but measurable BMD changes take months. In the Fracture Intervention Trial (FIT), alendronate over 3 years reduced vertebral fracture risk by 47% in women with existing fractures compared to placebo. Those are meaningful outcomes, but they accumulate over years of sustained use, not months.

Typical lumbar spine BMD gains with alendronate run 4-8% over 3 years, depending on baseline T-score, calcium and vitamin D status, and adherence. Gains plateau after several years of use, and a drug holiday at year 5 is standard practice for most women without very high fracture risk.

Romosozumab: Rapid Anabolic Drive in Year One

The ARCH trial (NEJM 2017) randomized 4,093 postmenopausal women with osteoporosis and prior vertebral fracture to romosozumab 210 mg monthly versus alendronate. At 12 months, romosozumab produced lumbar spine BMD gains of approximately 13%, compared to approximately 5% for alendronate. Hip BMD gains were similarly superior.

The WomanRx clinical team describes this as the "front-load strategy": use romosozumab's anabolic window to rapidly raise BMD in the first 12 months, then transition to an antiresorptive (typically alendronate or zoledronic acid) to hold those gains. Women who start with alendronate and later add romosozumab see smaller additional gains than those who begin with romosozumab first. Sequence matters.

The 12-Month Cap on Romosozumab

Romosozumab is not indefinitely titrated. The FDA-approved labeling limits romosozumab to 12 monthly doses. After that, continuing therapy with a bisphosphonate like alendronate or zoledronic acid is required to preserve the BMD built during the anabolic phase. Stopping romosozumab without a follow-on therapy causes rapid BMD loss back toward baseline within 12-24 months.

Tolerability: What Side Effects Are You Actually Likely to Experience?

Alendronate Tolerability

Alendronate's most common complaint is upper gastrointestinal irritation: reflux, esophagitis, and nausea. These are real and drive a lot of discontinuation in real-world practice. The weekly formulation (70 mg) substantially reduced GI events compared to the original daily 10 mg dose. To minimize GI side effects, you must take alendronate:

• First thing in the morning, with at least 6-8 oz of plain water
• At least 30 minutes before any food, drink, or other medication
• Remaining upright (sitting or standing) for 30 minutes after

Women with Barrett's esophagus, active esophageal disease, or severe gastroesophageal reflux disease should avoid alendronate entirely.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures are rare but real long-term concerns. The absolute risk is low: atypical femoral fractures occur in approximately 3.2-50 per 100,000 person-years of bisphosphonate use, a risk that rises with duration of use beyond 5 years. This is why the drug holiday conversation starts at year 5 for most women.

Romosozumab Tolerability

Romosozumab is generally well tolerated locally. Injection-site reactions occur in about 11% of users and are the most frequently reported side effect. Arthralgias, headache, and muscle spasms are reported in small percentages.

The more serious tolerability concern is cardiovascular. The ARCH trial found a numerically higher rate of serious cardiovascular events (cardiac ischemic events and cerebrovascular events) in the romosozumab group compared to the alendronate group: 1.8% vs 1.2% in year one of the ARCH trial. This signal led the FDA to add a boxed warning for myocardial infarction and stroke risk. The drug is contraindicated if you have had a heart attack or stroke in the past year.

This cardiovascular signal does not appear to have a clear biological mechanism yet, and some experts consider it a statistical artifact of the ARCH population. The evidence gap is real: we do not have large, dedicated cardiovascular safety trials in women with no prior cardiac history. If you have cardiovascular risk factors, this must be discussed explicitly with your prescriber.

Sex-Specific Physiology: How Hormones and Life Stage Change Everything

Postmenopause: The Primary Target Population

Both drugs are studied and approved primarily for postmenopausal women. After menopause, estrogen deficiency accelerates bone resorption markedly. Women lose approximately 1-2% of bone density per year in the first 5 years after menopause, and some women lose considerably more. Both alendronate and romosozumab are approved specifically for postmenopausal osteoporosis, meaning a T-score at or below -2.5 at the lumbar spine or hip, or a T-score between -1.0 and -2.5 with high fracture risk.

Perimenopause

Bone loss can begin in late perimenopause, sometimes several years before the final menstrual period. At this stage, pharmacologic treatment for osteoporosis is less commonly initiated, but a DXA scan and fracture risk assessment with FRAX are clinically appropriate if you have risk factors. Neither alendronate nor romosozumab is specifically indicated for perimenopause osteopenia; lifestyle optimization and possibly menopausal hormone therapy (MHT) are first-line considerations.

Reproductive Years and PCOS

Premenopausal osteoporosis is uncommon but can occur with amenorrhea (including hypothalamic amenorrhea, anorexia-related bone loss, or premature ovarian insufficiency). Romosozumab is not approved in premenopausal women. Alendronate is occasionally used off-label in premenopausal osteoporosis but requires careful discussion about pregnancy risk (see below).

Women with polycystic ovary syndrome (PCOS) may have altered bone density due to hyperandrogenism and metabolic factors, though the relationship is complex. If you have PCOS and are concerned about bone health, a DXA scan at menopause or earlier if you have risk factors is appropriate.

Pregnancy, Lactation, and Contraception: Critical Safety Section

Both alendronate and romosozumab are contraindicated in pregnancy. If there is any chance you could become pregnant, reliable contraception is required during treatment and for some time after.

Alendronate in Pregnancy and Lactation

Alendronate carries Pregnancy Category X designation in older FDA labeling (pre-2015 category system). Under the current Pregnancy and Lactation Labeling Rule, available data indicate skeletal abnormalities and reduced pup survival in animal studies at doses approximating human exposure. Bisphosphonates incorporate into bone and can theoretically be released during future pregnancies, crossing the placenta. Case reports in women who conceived after bisphosphonate use do not show a consistent pattern of fetal harm, but the data set is small and safety is not established.

Alendronate is poorly absorbed and likely transfers minimally into breast milk, but no adequate human lactation data exist. Breastfeeding during alendronate therapy is not recommended.

Given that alendronate is primarily used in postmenopausal women, pregnancy is rarely a concern in practice. For younger women with premenopausal osteoporosis treated with alendronate, contraception counseling is mandatory, and the drug should be discontinued as soon as a pregnancy is confirmed (or planned).

Romosozumab in Pregnancy and Lactation

Animal studies of romosozumab demonstrated fetal skeletal changes and developmental toxicity. There are no adequate human pregnancy data. Romosozumab should not be used in pregnancy. Women of reproductive potential must use effective contraception during treatment.

Romosozumab transfer into human breast milk is unknown. Because it is a monoclonal antibody, some transfer is expected, but the clinical significance is unclear. Breastfeeding is not recommended during romosozumab therapy.

Since romosozumab is approved only for postmenopausal women, these considerations apply primarily to women treated off-label or to those who are perimenopausal with ongoing ovarian function. If you have any menstrual cycle activity, confirm pregnancy status before each monthly romosozumab injection.

Who This Treatment Is Right For (and Who Should Reconsider)

Alendronate Is Likely a Better Fit If You

• Have newly diagnosed osteoporosis with moderate fracture risk and no prior vertebral fracture
• Are comfortable with a weekly oral pill and can follow the strict dosing instructions
• Have no esophageal disease or severe reflux
• Need long-term therapy extending beyond 12 months without switching
• Have a history of cardiovascular disease or recent MI or stroke that makes romosozumab too risky
• Are in the early postmenopausal years and building a long-duration bone preservation strategy

Romosozumab Is Likely a Better Fit If You

• Have severe osteoporosis with a T-score at or below -2.5 plus one or more prior vertebral fractures
• Need to build bone density rapidly, for example before a planned orthopedic procedure or because of accelerating fracture risk
• Have been on alendronate for years and are considering a drug holiday, then want to rebuild bone before resuming an antiresorptive
• Can tolerate monthly injections
• Have no history of MI or stroke in the past 12 months and acceptable cardiovascular risk

Who Should Avoid Both

Women with hypocalcemia must have this corrected before starting either drug. Severe renal impairment (estimated glomerular filtration rate below 35 mL/min) is a contraindication for alendronate. Romosozumab's safety in severe renal impairment is not established.

Switching From Fosamax to Evenity: What the Evidence Shows

Switching from alendronate to romosozumab is a recognized clinical strategy, but the timing and rationale matter.

If you have been on alendronate for several years and your BMD has plateaued or you have sustained a fracture despite therapy, switching to romosozumab is a reasonable escalation. The ARCH trial included women who were treatment-naive to romosozumab, and the gains were substantial. However, prior bisphosphonate use may slightly blunt romosozumab's anabolic effect compared to drug-naive patients, because bisphosphonates suppress bone turnover, and romosozumab needs some baseline turnover to stimulate formation.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis recommends sequential therapy for women at very high fracture risk: start with an anabolic agent (romosozumab or teriparatide), then follow with an antiresorptive. If you started with alendronate and need to escalate, switching to romosozumab for 12 months followed by returning to alendronate (or switching to zoledronic acid) is a well-supported approach.

Do not do the reverse: starting with romosozumab and then switching to alendronate maintains your gains, but starting with alendronate and then adding romosozumab produces smaller additional BMD gains than the anabolic-first sequence. The ARCH trial specifically compared romosozumab-to-alendronate versus alendronate-to-alendronate and demonstrated that the anabolic-first arm reduced new vertebral fracture risk by 48% over 24 months versus continuous alendronate.

Monitoring and Follow-Up: What to Expect During Treatment

During Alendronate Therapy

• DXA scan at baseline and every 1-2 years initially, then every 2-3 years once stable
• Serum calcium and 25-hydroxyvitamin D before starting; correct deficiencies first
• Bone turnover markers (CTX, P1NP) are not routinely required but can confirm adherence and response
• At year 5, your provider will reassess fracture risk to decide on a drug holiday versus continued treatment; women with T-score above -2.5 at the femoral neck and no prior fractures are generally candidates for a holiday

During Romosozumab Therapy

• Baseline serum calcium and vitamin D; hypocalcemia must be corrected before dose one
• Dental examination before starting, given the theoretical ONJ risk (shared with bisphosphonates but lower with romosozumab)
• Cardiovascular risk assessment before prescribing; document absence of recent MI or stroke
• BMD and bone turnover markers at 6 and 12 months
• Plan your follow-on antiresorptive therapy before you start; the transition at month 13 is not optional

Regardless of which medication you take, adequate calcium (1,000-1,200 mg/day from food and supplements combined) and vitamin D (800-2,000 IU/day based on serum levels) are required for either drug to work. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends women over 50 aim for 1,200 mg of calcium daily.

What the Evidence Gap Looks Like for Women

Women have been the majority of osteoporosis trial participants, which is a relative strength compared to most fields. The FIT trial enrolled postmenopausal women specifically. The ARCH trial enrolled postmenopausal women. So the direct evidence base here is better than in many therapeutic areas.

What remains less studied is the experience of premenopausal women with osteoporosis, women with premature ovarian insufficiency, and women on gender-affirming hormone therapy. Romosozumab has not been studied in these populations. Alendronate data in premenopausal women are limited to case series and small trials. If you fall into any of these groups, your prescriber is working with extrapolated data, and you should ask explicitly what the evidence level is for your specific situation.

The cardiovascular signal in ARCH also deserves more scrutiny in women without prior cardiovascular disease. The ARCH population was older with a mean age of 74 and high rates of prior fracture, which limits how well the cardiovascular risk data apply to a younger postmenopausal woman in her late 50s with no cardiac history. The American Heart Association's statement on osteoporosis treatments and cardiovascular risk notes that the absolute cardiovascular risk difference in ARCH was small but real, and individual cardiovascular risk assessment remains essential before prescribing romosozumab.